Israel’s Can-Fite BioPharma has reported success in the Phase I/II clinical trial of its CF102 (Namodenoson) treatment for liver cancer (hepatocellular carcinoma or HCC). It was also successful in Phase I/II trials for treating Hepatitis C. http://www.globes.co.il/serveen/globes/docview.asp?did=1000712199&fid=1725